InnoSIGN
The explosion of omics data, especially from high-throughput RNA sequencing, has transformed the biomedical research landscape. However, this overwhelming amount of data has also created a bottleneck-- researchers and clinicians are now inundated with complex datasets that are challenging to interpret and translate into actionable insights. InnoSIGN, a Philips Research spin out, addresses this critical need through its flagship product, Comprehensive Pathway Analysis (CPA). CPA bridges the gap between raw RNA data and by delivering a visual roadmap of functional signaling activity. This platform holds profound implications for pharmaceutical research, drug discovery, and precision medicine, particularly in patient stratification and treatment response prediction across a wide range of disease areas.Content by InnoSIGN
| 2 min read
Collaboration combines Scipher’s unique RNAseq data with InnoSIGN’s proprietary comprehensive pathway analysis (CPA) platform to enhance the understanding of complex immune-mediated diseases.
Page 1 of 1 - 1 Total Items
